Ascimib 40 MG (Asciminib)

Basic Product Information of Ascimib 40 MG (Asciminib)

How Ascimib 40 MG (Asciminib) Works: STAMP Inhibition and Allosteric BCR-ABL1 Blockade

Asciminib, the active ingredient in Ascimib 40 MG, is the world’s first approved STAMP inhibitor, an acronym standing for Specifically Targeting the ABL Myristoyl Pocket. This designation defines a mechanistically unique drug class that distinguishes asciminib from all five previously approved BCR-ABL1 tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib, bosutinib, and ponatinib), each of which functions as an ATP-competitive inhibitor binding the ATP-binding site within the BCR-ABL1 kinase domain. Asciminib instead binds the myristoyl pocket, a deep hydrophobic regulatory site located at the C-terminal lobe of the ABL1 kinase domain, a site that is biologically accessible only in the ABL1 kinase and not in other tyrosine kinases, conferring exceptional target selectivity.

In the normal, non-oncogenic state, the myristoyl group at the N-terminus of ABL1 protein occupies this pocket in a cis-intramolecular interaction, clamping the kinase in an inactive conformation. BCR-ABL1, the oncogenic fusion protein produced by the Philadelphia chromosome translocation t(9;22)(q34;q11) that defines chronic myeloid leukemia (CML), lacks the N-terminal myristoyl group due to the fusion event, removing this intramolecular autoinhibitory mechanism and leaving BCR-ABL1 constitutively active. Asciminib re-establishes allosteric inhibition by occupying the now-unoccupied myristoyl pocket, restoring the inactive ABL1 kinase conformation, suppressing BCR-ABL1 kinase activity, and blocking the downstream JAK-STAT, RAS-MEK-ERK, and PI3K-AKT-mTOR signaling cascades that drive CML cell proliferation and survival.

Because asciminib does not bind the ATP-binding site, it retains potent anti-leukemic activity against the large majority of BCR-ABL1 kinase domain point mutations that cause resistance to ATP-competitive TKIs, including mutations at the P-loop, T315I gatekeeper position (at the 200 mg twice-daily dose), and SH3/SH2 regulatory domain mutations, providing an orthogonal mechanism of resistance circumvention.

Ascimib 40 MG delivers the 40 mg unit dose component of asciminib therapy. For CML-CP patients previously treated with two or more TKIs (the primary indication based on the ASCEMBL trial), the reference-label dose is 40 mg (one 40 mg tablet) administered orally twice daily on an empty stomach, with at least two hours of fasting before each dose and at least one hour without food after each dose, to ensure consistent drug absorption.

At 40 mg twice daily (two tablets per day), one 30’s pot of Ascimib 40 MG provides a 30-day supply. A critically important and mechanistically unique feature of asciminib is its ability to function in combination with ATP-competitive TKIs, producing synergistic anti-leukemic activity in preclinical BCR-ABL1-positive cell line models through simultaneous dual-site blockade of BCR-ABL1 kinase activity: asciminib at the myristoyl pocket and an ATP-competitive TKI at the ATP-binding site.

This combination concept has advanced into clinical investigation as a strategy to prevent the emergence of resistant clones, given that a BCR-ABL1 mutant resistant to myristoyl-pocket binding (such as the I502L/V506L asciminib resistance mutation) would retain full sensitivity to ATP-competitive TKIs, and vice versa. Oncologists building comprehensive programs for CML and related myeloid malignancies can review the complete range of leukemia medicines at Mediaid Pharmacy for companion and supportive therapies.

In the pivotal ASCEMBL Phase 3 randomized, open-label trial, asciminib 40 mg twice daily was compared with bosutinib 500 mg once daily in 233 adults with CML-CP previously treated with two or more TKIs; patients with documented BCR-ABL1 T315I mutations were excluded from ASCEMBL. The primary endpoint, MMR at 24 weeks per blinded central laboratory assessment, was achieved by 25.5% of asciminib-treated patients versus 13.2% of bosutinib-treated patients (odds ratio 2.27; 95% CI 1.10 to 4.70; p=0.029).

The complete cytogenetic response (CCyR) rate at 24 weeks was 40.8% with asciminib versus 24.5% with bosutinib. The rate of treatment discontinuation due to adverse events was dramatically lower with asciminib (5.8%) than with bosutinib (21.1%), reflecting the superior tolerability profile of asciminib compared with a third-generation ATP-competitive TKI in heavily pre-treated CML patients. These results established asciminib as a standard-of-care precision medicine option for adult CML-CP patients after failure of two or more prior TKIs, a patient population with historically limited and poorly tolerated second-line-plus options.

Approved Indications of Asciminib (Reference Label for Ascimib 40 MG (Asciminib))

Asciminib, the active ingredient in Ascimib 40 MG, carries reference-label indications across two distinct CML clinical settings: third-line-plus CML-CP (without T315I mutation) at 40 mg twice daily, and CML-CP or CML-AP with confirmed BCR-ABL1 T315I mutation at 200 mg twice daily. The 40 mg tablet strength of Ascimib directly supports the first-indication dose of 40 mg twice daily (one tablet per dose), and also enables the T315I-indication dose of 200 mg twice daily when five 40 mg tablets are administered per dose. Both dosing schedules require administration on an empty stomach. BCR-ABL1 T315I mutation testing by validated molecular assay is mandatory before prescribing the 200 mg twice-daily dose. Prescribers should confirm the exact locally approved indications on the Ascimib product label and applicable national hematology guidelines before initiating treatment.

Key Clinical Benefits of Ascimib 40 MG (Asciminib)

Clinical Monitoring Requirements During Ascimib 40 MG (Asciminib) Treatment

Hematologic monitoring is the primary ongoing safety requirement during asciminib therapy. Myelosuppression, including thrombocytopenia (platelet count decrease), neutropenia, and anemia, is a pharmacological effect of BCR-ABL1 inhibition across the entire TKI class and is observed with asciminib at clinical doses. The reference label requires a complete blood count (CBC) with differential at baseline and monthly during the first three months of treatment, then periodically as clinically indicated thereafter.

Grade 3 thrombocytopenia (platelet count 25,000 to less than 50,000 per microliter) requires withholding asciminib until platelet count recovers to 50,000 per microliter or above, then restarting at a reduced dose; Grade 4 thrombocytopenia (platelet count below 25,000 per microliter) requires withholding asciminib until platelet count recovers to 75,000 per microliter or above before resuming, also at a reduced dose. Neutropenia management follows an analogous dose-modification algorithm based on absolute neutrophil count (ANC) thresholds.

Oncology nurses and hematologists must evaluate CBC trends at each visit, particularly during the first treatment cycle when myelosuppressive nadir is most likely, and adjust dose or schedule per the prescribing label guidelines. Patients should be counseled to report any unusual bruising, bleeding, signs of infection, or unexplained fatigue immediately to their oncology team.

Pancreatic enzyme monitoring is a mandatory safety assessment unique to asciminib among approved BCR-ABL1 inhibitors. The reference label requires serum lipase and amylase measurement at baseline and monthly during the first three months of treatment, then as clinically indicated thereafter. Asymptomatic grade 1 to 2 lipase or amylase elevation does not require dose modification but should trigger increased monitoring frequency; Grade 3 or 4 pancreatic enzyme elevation (with or without symptoms of pancreatitis including epigastric pain radiating to the back, nausea, or vomiting) requires dose withholding and clinical evaluation for acute pancreatitis before any decision to resume asciminib. Patients should be advised to maintain adequate hydration throughout therapy, limit alcohol consumption, and report any epigastric or upper abdominal pain promptly.

Cardiovascular monitoring is required throughout asciminib therapy because arterial occlusive events, including peripheral arterial occlusive disease (PAOD), ischemic cerebrovascular events, and cardiac ischemia, have been reported across the BCR-ABL1 TKI drug class. Asciminib prescribers should assess and optimize cardiovascular risk factors (hypertension, dyslipidemia, diabetes, smoking, and obesity) at baseline and throughout treatment; blood pressure measurement at every clinic visit is advisable. Electrocardiogram (ECG) monitoring for QTc prolongation, while less demanding with asciminib than with some other TKIs, should be performed at baseline and as clinically indicated in patients with pre-existing cardiac conduction abnormalities or who require co-administration of QTc-prolonging medications.

Drug Interactions and Important Safety Information for Ascimib 40 MG (Asciminib)

The most clinically significant drug interaction categories for asciminib involve CYP3A4 pathway agents, P-glycoprotein (P-gp) and BCRP substrates, and food and acid-suppressing medications. Asciminib is primarily metabolized by CYP3A4, with additional contributions from CYP2C9 and phase II glucuronidation pathways. Strong CYP3A4 inducers (including rifampin, rifabutin, carbamazepine, phenytoin, enzalutamide, and St. John’s Wort) significantly reduce asciminib plasma exposure, potentially rendering therapy sub-therapeutic; co-administration with strong CYP3A4 inducers should be avoided throughout the treatment course.

If a strong CYP3A4 inducer is clinically unavoidable, the treating oncologist should be aware that no validated dose adjustment has been established to reliably compensate for the interaction and should consider alternative medications. Strong CYP3A4 inhibitors (including azole antifungals such as ketoconazole, itraconazole, and voriconazole; macrolide antibiotics such as clarithromycin; and ritonavir-containing antiretroviral regimens) may increase asciminib plasma concentrations and potentially increase the risks of myelosuppression and pancreatitis; if co-administration is unavoidable, more frequent CBC and pancreatic enzyme monitoring is warranted.

Asciminib is an inhibitor of CYP2C9 at clinically relevant concentrations; co-administration with CYP2C9 substrates that have a narrow therapeutic index (including warfarin, phenytoin, and certain sulfonylurea antidiabetic agents) may increase the plasma concentrations of those co-medications, necessitating closer monitoring and potential dose adjustment of the CYP2C9 substrate drug. Asciminib is also a substrate and inhibitor of P-gp and BCRP efflux transporters; co-administration with P-gp inhibitors may increase asciminib exposure, while P-gp inducers (including rifampin) may reduce it. For patients co-administered BCRP substrate medications (including rosuvastatin and certain fluoroquinolone antibiotics), asciminib-mediated BCRP inhibition may increase their systemic exposure; monitoring for substrate drug toxicity and dose adjustment as needed are advisable.

The fasting requirement for asciminib (no food for at least 2 hours before and 1 hour after each dose) creates a clinically meaningful food-drug interaction that must be communicated clearly to every patient starting treatment: consuming food close to the dosing window significantly reduces asciminib bioavailability. Proton pump inhibitors (PPIs) and H2-receptor antagonists do not significantly affect asciminib absorption (asciminib solubility is not pH-dependent), making acid suppression management less complex for asciminib than for some other CML targeted agents. Patients must provide their hematologist or oncologist with a complete medication list, including all prescription drugs, over-the-counter products, vitamins, and herbal supplements, before and throughout Ascimib 40 MG treatment. Clinicians co-sourcing companion oncology or supportive care medicines alongside asciminib can browse the full oncology medicines range available at Mediaid Pharmacy.

Side Effects and Precautions of Ascimib 40 MG (Asciminib)

Who Should Use Ascimib 40 MG (Asciminib)?

Ascimib 40 MG (Asciminib) is indicated for adult patients with CML in chronic phase (CML-CP) who have been previously treated with two or more BCR-ABL1 tyrosine kinase inhibitors, where asciminib monotherapy at 40 mg twice daily is the reference-label dose validated in the ASCEMBL Phase 3 trial (MMR rate 25.5% at 24 weeks vs. 13.2% with bosutinib; OR 2.27; p=0.029; CCyR rate 40.8% vs. 24.5%; treatment discontinuation due to adverse events 5.8% vs. 21.1% in 233 patients).

Ascimib 40 MG is also used at the 200 mg twice-daily dose (five 40 mg tablets per dose) for adult patients with CML-CP or CML-AP harboring a confirmed BCR-ABL1 T315I mutation, regardless of the number of prior TKIs received, where asciminib STAMP inhibition provides potent anti-leukemic activity against a mutation that is broadly resistant to all ATP-competitive BCR-ABL1 TKIs. BCR-ABL1 T315I mutation status must be confirmed by a validated molecular diagnostic assay before prescribing the 200 mg twice-daily dose; patients without T315I who have received fewer than two prior TKIs should be assessed for eligibility for earlier-line TKI options before starting asciminib.

Before initiating Ascimib 40 MG at either dose, prescribers should evaluate baseline CBC with differential, serum lipase and amylase, cardiovascular risk factor profile, blood pressure, and hepatic function. Asciminib must be taken on an empty stomach at all doses; patients should be counseled on the strict fasting requirement (no food for 2 hours before and 1 hour after each dose) before starting treatment. For patients requiring companion oncology medicines or supportive care agents alongside their asciminib regimen, the Mediaid Pharmacy Everest Pharmaceuticals medicines range and the broader oncology medicines portfolio offer a comprehensive selection available for worldwide delivery.

Global Supplier: Mediaid Pharmacy Worldwide Shipping for Ascimib 40 MG (Asciminib)

Mediaid Pharmacy is a Dhaka-based supplier of oncology and specialty medicines with worldwide shipping. Ascimib 40 MG (Asciminib), manufactured by Everest Pharmaceuticals Ltd. in Bangladesh, is available in 30’s pot tablet packs, and all orders are supported by pricing quotations, stock confirmation, regulatory documentation, and end-to-end delivery tracking. Hospitals, specialist hematology and oncology clinics, distributors, and patients can contact the Mediaid Pharmacy team through WhatsApp, phone, or WeChat for all inquiries about Ascimib 40 MG Asciminib stock, pricing, and international delivery timelines. Buyers sourcing asciminib for third-line-plus CML-CP programs, T315I mutation-directed CML therapy, or co-sourcing multiple oncology medicines in a single shipment can browse the complete leukemia medicines collection and the broader oncology medicines collection at Mediaid Pharmacy before requesting a consolidated quotation.

Why Choose Ascimib 40 MG (Asciminib) from Mediaid Pharmacy?

Ascimib 40 MG (Asciminib) provides hematology and oncology teams with the reference-label 40 mg unit dose of asciminib, the foundational tablet strength that enables the standard 40 mg twice-daily therapeutic dose validated in the ASCEMBL Phase 3 trial (25.5% MMR at 24 weeks and a 5.8% toxicity discontinuation rate in TKI-pretreated CML-CP patients) and supports the complete dose-reduction ladder as well as the T315I-specific 200 mg twice-daily regimen (five 40 mg tablets twice daily). At 40 mg twice daily (two tablets per day), the 30’s pot provides a full 30-day supply, matching the standard monthly oncology dispensing cycle and streamlining supply management for long-term continuous CML therapy. Ascimib 40 MG is manufactured by Everest Pharmaceuticals Ltd., a Bangladesh-based pharmaceutical manufacturer with registration in Bangladesh, and is supplied in a 30’s pot tablet pack suited to the continuous twice-daily dosing schedule required for both CML-CP and T315I-mutated CML indications. Mediaid Pharmacy supplies Ascimib 40 MG with full product documentation, specialist supply support, and worldwide shipping from Dhaka, with every order beginning from a prescription-based inquiry that aligns supply with clinical need. To source additional leukemia medicines, Everest Pharmaceuticals-branded products, or broader oncology medicines alongside Ascimib 40 MG, visit the Mediaid Pharmacy Everest Pharmaceuticals medicines section and contact the team for a personalized quotation.

Frequently Asked Questions About Ascimib 40 MG (Asciminib)